Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 positive |
| Therapy | Alofanib |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 positive | triple-receptor negative breast cancer | sensitive | Alofanib | Preclinical - Cell culture | Actionable | In a preclinical study, Alofanib (RPT835) treatment led to inhibition of cell proliferation in triple-receptor negative breast cancer cell lines expressing FGFR2 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27136102). | 27136102 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27136102) | Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. | Full reference... |